Scientists ad Michigan Civitatis-sicut virus particula dicitur Universitas sunt malitiosis Qβ, quod generate anti-cancer et immune responsum et esse in corpore sicut cancer curatio nova vaccine. US $ 2.4 decies project funded per National Cancri Instituti et sustinere progressum cancer cellulis, qui sunt currently de vaccina praesidio animalium: violenta sagitta, et bene sit vaccini sponte cancer in hominibus.
Qβ particulas includunt tumor et dolor meus in combinant-consociata antigens carbohydrate (TACAs), et his qui credunt in antigens producendum completum tumor anti-cell securitatem et incrementum tumore ne redigendum tumor development. Insuper et inquisitores ut develop Qβ uti crystal structuram ex elementorum et promovere mutationes, redigendum toxicus desideravit minimos, qui etiam possunt occidere cancer cellulis. Haec est prima huiusmodi iudicium Taca Vaccinum exemplar usus.
This vaccine will be used first to treat canine cancer and will focus on osteosarcoma, which is a refractory dog and human bone tuberculum.
Vaccines can reduce tumor growth and protect patients from tumor progression and further progress. If we can further understand the relationship between the structural characteristics of Qβ-TACA and anti-tumor immunity, it can have a great effect on the design of cancer vaccina. This research also strengthens the important role of veterinary medicine in cancer research.
Yuzbasiyan Gurkan, dixit: "Spontanea cancer felium et canum in in test cancer vaccina ipsa praebet. Hoc est unum ex multis exempli gratia quae est in VETERINARIUS medicinae investigationis quod homo se possit prodesse. "
